Dog colonoscopy model for predicting human colon absorption

Pharmaceutical Research

Volumn 23, Issue 7, 2006, Pages 1554-1563

  Sutton, Steven C ^a   Evans, Loreen A ^a   Fortner, Jay H ^a   McCarthy, Jennifer M ^a,b   Sweeney, Kathy ^a  

^a PFIZER INC   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

Aminophylline; Atenolol; Azithromycin; Biopharmaceutics classification scheme; CJ 13610; CP 331684; CP 409092; CP 424391; Nifedipine; Propranolol; Sertraline; Trovafloxacin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMINOPHYLLINE; ATENOLOL; AZITHROMYCIN; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CAPROMORELIN; CJ 013610; CJ 013670; CP 331684; CP 409092; LIPOXYGENASE INHIBITOR; NIFEDIPINE; PROPRANOLOL; SERTRALINE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANUS SPHINCTER; ARTICLE; COLON; COLONOSCOPY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG SOLUBILITY; ENDOSCOPE; FEMALE; HYDROPHILICITY; INTESTINE MUCOSA PERMEABILITY; INTUBATION; MALE; MODEL; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; AMINOPHYLLINE; ANIMALS; ATENOLOL; BIOLOGICAL AVAILABILITY; COLONOSCOPY; DELAYED-ACTION PREPARATIONS; DOGS; GASTROINTESTINAL TRANSIT; HUMANS; IMIDAZOLES; INTESTINAL ABSORPTION; MODELS, ANIMAL; MODELS, BIOLOGICAL; NIFEDIPINE; PERMEABILITY; SOLUBILITY; SULFIDES;

EID: 33745685164     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0252-3     Document Type: Article

References (45)

1. L. R. Johnson 1994 Physiology of the Gastrointestinal Tract. vol. I Raven Press New York 633
2. P. Bieck 1993 Colonic Absorption and Metabolism Marcel Dekker NY
3. N. Rietbrock 1987 Drug Absorption from Different Regions of the Human GI Tract: Methods of Investigation and Results Vieweg and Sohn Braunschweig/ Wiesbaden
4. B. Henry, K. Horspool, M. Humphrey, and J. Nuttall. Absorption of peptide-like drugs, Formulations of poorly-available drugs for oral administration, APGI & Swedish Academy of Pharmaceutical Sciences, Editions de Sante, Paris, 1996, pp. 195-198.
5. R. Oberle H. Das 1994 Variability in gastric pH and delayed gastric emptying in Yucatan miniature pigs Pharm. Res. 11 592 594
6. J. Kim R. Oberle D. Krummel J. Dressman D. Fleisher 1994 Absorption of ACE inhibitors from small intestine and colon J. Pharm. Sci. 83 1350 1356
7. J. Tibbits 2003 Issues related to the use of canines in toxicologic pathology-issues with pharmacokinetics and metabolism Toxicol. Pathol. 31 Suppl 17 24
8. J. Fix K. Engle P. Porter P. Leppert S. Selk C. Gardner J. Alexander 1986 Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract Am. J. Physiol. 250 G332 G340
9. L. Meunier J. Kissinger J. Marcello A. Nichols P. Smith 1993 A chronic access port model for direct delivery of drugs into the intestine of conscious dogs Lab. Animal. Sci. 43 466 470
10. N. J. Clear A. Milton M. Humphrey B. T. Henry M. Wulff D. J. Nichols R. J. Anziano I. Wilding 2001 Evaluation of the Intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon Eur. J. Pharm. Sci. 13 375 384
11. S. C. Sutton K. Engle M. Cortese 1991 Conscious dog model for the study of colon absorption and dosage formulation performance in the colon Pharm. Res. 8 S159
12. FDA. Guidance for Industry: Waiver of in Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Containing Certain Active Moieties/Active Ingredients Based on a Biopharmaceutics Classification System., CDER, Rockville, 2000.
13. M. A. Bach M. Cambria 1999 Growth hormone releasing peptides: growth studies Curr. Opin. Endocrinol. Diabetes 6 100 105
14. J. T. [tmp] MacAndrew S. S. Ellery M. A. Parry L. C. Pan S. C. Black 2001 Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury Eur. J. Pharmacol. 432 195 202
15. T. Mano, R. W. Stevens, K. Ando, K. Nakao, Y. Okumura, M. Sakakibara, T. Okumura, K. Miyamoto, and T. Tamura. CJ-13610: Design of an Orally Active and Safe 5-LO Inhibitor, 22nd Symp. Med. Chem., Shizuoka, Japan, 2002, pp. 12-19.
16. Merck Index, Merck Research Laboratories, Whitehouse Station, 1997.
17. E. F. Fiese 2003 General pharmaceutics-the new physical pharmacy J. Pharm. Sci. 92 1331 1342
18. S. C. Sutton M. T. S. Rinaldi J. M. [tmp] McCarthy K. E. Vukovinsky 2002 A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression J. Pharm. Sci. 91 1046 1053
19. S. C. Sutton, M. T. S. Rinaldi, and K. E. Vukovinsky. Comparison of the gravimetric, phenol red and 14C-PEG-3350 methods to determine water absorption in the rat single pass intestinal perfusion model. AAPS Pharm. Sci. 3:article 25 (2001).
20. H. Bode E. Brendel G. Ahr U. Fuhr S. Harder 1996 Investigation of nifedipine absorption in different regions of the human git after simultaneous administration of 13C and 12C nifedipine Eur. J. Clin. Pharmacol. 50 195 201
21. S. C. Sutton L. Fournier K. Norton 1995 Dog colonoscopy model for predicting human colon absorption Pharm. Res. 12 S221
22. C. Hop Z. Wang Q. Chen G. Kwei 1998 Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening J. Pharm. Sci. 87 901 903
23. R. Teng T. G. Tensfeldt T. E. Liston G. Foulds 1996 Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography J. Chromatogr. B 675 53 59
24. A. H. Staib D. Loew S. Harder E. H. Graul R. Pfab 1986 Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled drug delivery device Eur. J. Clin. Pharmacol. 30 691 697
25. C. J. Fu W. D. Mason 1989 A simplified method for determination of nifedipine in human plasma by HPLC Anal. Lett. 22 2985 3002
26. R. M. Shepard G. S. Duthu R. A. Ferraina M. A. Mullins 1991 HPLC assay with EC detection of azithromycin in serum and tissues J. Chromatogr., B, Biomed. Appl. 565 321 337
27. S. Yee Z. Lin M. Gunduz S. Jaw-Tsai F. R. Nelson 2000 Effect of P-glycoprotein on the oral absorption and brain penetration of CP-409,092 in rats and mice Drug Metab. Rev. 32 194
28. P. A. Carpino, B. A. Lefker, S. M. Toler, L. C. Pan, J. Hadcock, P. Dasilva-Jardine, J. Pettersen, and D. Thompson. Short- and long-acting growth hormone secretagogues: discovery and SAR of capromorelin tartrate (CP-424391-18, American Chemical Society National Meeting, Chicago, IL, 2001.
29. D. Taylor R. Grundy B. Loveday 1981 Chronic dog intestinal loop model for studying drug absorption as exemplified by beta-adrenoreceptor blocking agents, atenolol and propranolol J. Pharm. Sci. 70 516 521
30. A. Buch W. Barr 1998 Absorption of propranolol in humans following oral, jejunal, and ileal administration Pharm. Res. 15 953 957
31. K. C. Waterman S. C. Sutton 2003 A computational model for particle size influence on drug absorption during controlled-release colonic delivery J. Control. Release 86 293 304
32. J. Dressman K. Yamada 1991 Animal models for oral drug absorption P. Welling F. Tse Pharmaceutical Bioequivalence Dekker New York 235 266
33. D. Luke, P. Going, G. Foulds, and G. Melnik. Bioavailability of azithromycin when delivered as a rectal solution to healthy subjects, The Third International Conference on the Mac rolides, Azalides and Streptogramins, Lisbon, Portugal, 1996, Abstract #4.25.
34. R. Sokal F. Rohlf 1981 Biometry WH Freeman New York
35. E. L. LeCluyse S. C. Sutton 1997 In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement Adv. Drug Deliv. Rev. 23 163 183
36. V. D. Makhey A. Guo D. A. Norris P. Hu J. Yan P. J. Sinko 1998 Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells Pharm. Res. 15 1160 1167
37. P. Wade J. Chen B. Jaffe I. Kassem R. Blakely M. Gershon 1996 Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract J. Neurosci. 16 2352 2364
38. N. H. Kasim M. Whitehouse C. Ramachandran M. Bermejo H. Lennernäs A. S. Hussain H. E. Junginger S. A. Stavchansky K. K. Midha V. P. Shah G. L. Amidon 2003 Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 85 96
39. D. Friedman G. L. Amidon 1989 Passive and carrier mediated intestinal absorption components of two ACE inhibitor prodrugs in rats: enalapril and fosinopril Pharm. Res. 6 1043 1047
40. W. L. Chiou H. Jeong S. Chung W. TC 2000 Evaluation of using the dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans Pharm. Res. 17 135 140
41. W. L. Chiou A. Barve 1998 Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats Pharm. Res. 15 1792 1795
42. S. A. Riley M. Kim F. Sutcliffe M. Rowland L. A. Turnberg 1992 Absorption of polar drugs following caecal instillation in healthy volunteers Aliment. Pharmacol. Ther. 6 701 706
43. I. Moriguchi S. Hirono I. Nakagome H. Hirano 1994 Comparison of reliability of log P values for drugs calculated by several methods Chem. Pharm. Bull. 42 976 978
44. C. Hoyo-Vadillo G. Castaneda-Hernandez J. E. Herrera J. Vidal-Garate L. A. Salazar A. Moreno-Ramos F. Chavez L. Tena E. Hong 1989 Pharmacokinetics of Oral Nifedipine: Relevance of the Distribution Phase J. Clin. Pharmacol. 29 251 256
45. M. L. Martins M. A. Pierossi L. A. Moraes W. Ribeiro E. Abbib G. B. Mendes A. Poli G. De Nucci M. N. Muscara 1997 Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration Int. J. Clin. Pharmacol. Ther. 35 324 328